ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,669.82
      1.24%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lixte Biotechnology Holdings Inc (LIXT)

      7. Lixte Biotechnology Holdings Inc (LIXT) News

      LIXT

      Lixte Biotechnology (LIXT)

      Lixte Biotechnology Holdings Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LIXT
      DateTimeSourceHeadlineSymbolCompany
      04/24/20243:25PMAllPennyStocks.comMixed Shelf Filing Gives Micro Cap Delayed BoostNASDAQ:LIXTLixte Biotechnology Holdings Inc
      03/27/20243:35PMAllPennyStocks.comBiotech Steals The Show Following Pre-Clinical Data AnnouncementNASDAQ:LIXTLixte Biotechnology Holdings Inc
      03/27/20248:30AMGlobeNewswire Inc.NEW SCIENTIFIC PUBLICATION SHOWS LB-100, LIXTE’S LEAD CLINICAL COMPOUND, CAN FORCE CANCER CELLS TO GIVE UP THEIR CANCER-CAUSING PROPERTIESNASDAQ:LIXTLixte Biotechnology Holdings Inc
      03/21/20248:30AMGlobeNewswire Inc.LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer TreatmentsNASDAQ:LIXTLixte Biotechnology Holdings Inc
      02/27/20244:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      02/27/20248:30AMGlobeNewswire Inc.Professor René Bernards to Present New Pre-Clinical Data on LIXTE’s LB-100 at Joint Conference of European and American Associations for Cancer ResearchNASDAQ:LIXTLixte Biotechnology Holdings Inc
      02/26/202410:48AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      02/26/20248:30AMGlobeNewswire Inc.LIXTE Biotechnology Enters into Exclusive Immune Oncology Patent License Agreement with NINDS and NCINASDAQ:LIXTLixte Biotechnology Holdings Inc
      01/29/20248:30AMGlobeNewswire Inc.First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma TrialNASDAQ:LIXTLixte Biotechnology Holdings Inc
      11/28/20235:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      11/13/20232:28PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      11/13/20238:30AMGlobeNewswire Inc.LIXTE Biotechnology Provides Update on Clinical Progress and Expanding CollaborationsNASDAQ:LIXTLixte Biotechnology Holdings Inc
      11/09/20235:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/17/20235:27PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/16/20232:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/16/20238:30AMGlobeNewswire Inc.LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand CollaborationNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/10/20233:55PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/10/20233:47PMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/09/20238:30AMGlobeNewswire Inc.LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. KovachNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/05/20238:39PMEdgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/05/20238:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
      10/04/20236:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
      09/29/20234:05PMEdgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LIXTLixte Biotechnology Holdings Inc
      09/27/20236:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      09/27/20236:05AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LIXTLixte Biotechnology Holdings Inc
      09/26/20238:30AMGlobeNewswire Inc.LIXTE Appoints Bas van der Baan as President and Chief Executive OfficerNASDAQ:LIXTLixte Biotechnology Holdings Inc
      09/20/202311:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LIXTLixte Biotechnology Holdings Inc
      09/20/20238:30AMGlobeNewswire Inc.LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian CancerNASDAQ:LIXTLixte Biotechnology Holdings Inc
      08/22/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LIXTLixte Biotechnology Holdings Inc
      08/11/20234:20PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LIXTLixte Biotechnology Holdings Inc
       Showing the most relevant articles for your search:NASDAQ:LIXT